Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Northwest Biotherapeutics, Inc. Stockholders

Kirby McInerney LLP is investigating potential claims against Northwest Biotherapeutics, Inc. (“Northwest Bio” or the “Company”) (Nasdaq:NWBO) concerning whether the Company and its executives violated their fiduciary duties.

On June 19, 2014 shares of the Company fell during intraday trading $2.06 or 22.97% to trade at $6.91 after a report featured on TheStreet.com stated, “The prestigious MD Anderson Cancer Center issued a stern rebuke to Northwest Biotherapeutics (NWBO) for making promotional, unjustified claims about results from an ongoing clinical trial of an experimental cancer vaccine known as DCVax-Direct.” MD Anderson Cancer Center is running the DCVax-Direct clinical trial with funding from Northwest Biotherapeutics. According to the report, investigators at MD Anderson, one of several sites conducting the study, have not yet been able to analyze data collected because patients are still being enrolled and treated in the study.

If you are a Northwest Bio stockholder and have information that could assist in this investigation, please contact J. Brandon Walker, Esq. by email at bwalker@kmllp.com, or telephone at (212) 699-1145, Melissa Fortunato, Esq. by email at mfortunato@kmllp.com, or telephone at (212) 699-1141, toll free at (888) 529-4787, or by filling out this contact form. There is no cost or obligation to you.

Kirby McInerney LLP is a New York-based law firm concentrating in securities, stockholder, whistleblower, antitrust and consumer litigation. For additional information, please go to www.kmllp.com.

Kirby McInerney LLPJ. Brandon Walker, Esq., 212-699-1145bwalker@kmllp.comorMelissa Fortunato, Esq., 212-699-1141mfortunato@kmllp.comorToll Free: 888-529-4787

Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Mar 2024 to Apr 2024